Q-omics provides the consensus-scored KCNJ12 profile across patient tissues and cancer cell-line models. KCNJ12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, KCNJ12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KCNJ12 RNA expression shows 15,419 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where KCNJ12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ12 survival associations across molecular data types. KCNJ12 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ12 RNA expression–survival associations across cancer types. High KCNJ12 expression shows unfavorable associations in UCEC, ACC and LUSC, but favorable associations in MESO, UVM and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for KCNJ12 RNA expression.
This table summarizes KCNJ12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNJ12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ12 shows lower tumor expression in KIRC, KICH, KIRP, COAD, BRCA and LUSC. The KIRC box plot shows higher KCNJ12 RNA expression in normal versus tumor tissue (log2 FC = −1.776, t-test p < 0.001).
This table shows molecular features associated with KCNJ12 in patient tissues and cancer cell lines. In patient samples, KCNJ12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
